Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet + Xeloda dose-finding study in pretreated metastatic breast cancer
2005-005885-36Phase 2Completed
- Sponsor
- Azienda USL di Forlì
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and capecitabine in breast cancer, sponsored by Azienda USL di Forlì. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Mar 2006; status: completed.
02
Drugs
doxorubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005885-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005885-36.